This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Latest News
-
22nd March 2023
FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278
-
16th February 2023
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS
-
14th February 2023
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
News
-
22/03/2023
FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278
-
16/02/2023
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS
-
14/02/2023
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
-
30/01/2023
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE
-
12/01/2023
ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA